EcoDrugPlus

Mitogen-Activated Protein Kinase 10

Ensembl ID : ENSOMEG00000006819
Gene Symbol: MAPK10
1 Cross references
88 Possible Orthologues:

Mitogen-Activated Protein Kinase 11

Ensembl ID : ENSOMEG00000023468
Gene Symbol: MAPK11
1 Cross references
198 Possible Orthologues:

Mitogen-Activated Protein Kinase 14

Ensembl ID : ENSOMEG00000020288
Gene Symbol: MAPK14
3 Cross references
206 Possible Orthologues:

Mitogen-Activated Protein Kinase 14a

Ensembl ID : ENSOMEG00000023039
Gene Symbol: LOC112139315
3 Cross references
224 Possible Orthologues:

Mitogen-Activated Protein Kinase 8

Ensembl ID : ENSOMEG00000009255
Gene Symbol: MAPK8
3 Cross references
224 Possible Orthologues:

Mitogen-Activated Protein Kinase 8-Like

Ensembl ID : ENSOMEG00000002466
Gene Symbol: LOC112161471
4 Cross references
221 Possible Orthologues:

Mitogen-Activated Protein Kinase 9-Like

Ensembl ID : ENSOMEG00000005613
Gene Symbol: LOC112153234
2 Cross references
210 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase 1

Ensembl ID : ENSOMEG00000021273
Gene Symbol: MAP2K1
3 Cross references
214 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase 2

Ensembl ID : ENSOMEG00000004857
Gene Symbol: MAP2K2
3 Cross references
212 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 10

Ensembl ID : ENSOMEG00000013309
Gene Symbol: MAP3K10
3 Cross references
182 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 11

Ensembl ID : ENSOMEG00000000090
Gene Symbol: MAP3K11
3 Cross references
182 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 12

Ensembl ID : ENSOMEG00000019086
Gene Symbol: MAP3K12
3 Cross references
185 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).